Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

162 results about "Targeted nanoparticles" patented technology

Blood Clot-Targeted Nanoparticles

Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid / surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticle may further include biologically active agents, radionuclides, and / or other imaging agents, and are used to image and / or lyse blood clots in human subjects.
Owner:BARNES JEWISH HOSPITAL

Targeted nanoparticle drug for magnetic hyperthermia treatment on malignant tumors

The present invention relates to a targeted magnetic nanoparticle drug and the preparation method thereof. The targeted magnetic nanoparticle drug comprises an effector molecule and a guidance molecule in a weight ratio of 1:0.0001-0.20. The aforesaid effector molecule is a magnetic particle, with a particle size of not more than 1000 nm and a specific adsorption rate (SAR) of 10-7000 W / gFe. The aforesaid guidance molecule comprises an antibody, a ligand or a magnetic particle. The particle size of the aforesaid targeted drug is 2-1000 nm. The targeted magnetic nanoparticle drug is prepared by coupling a magnetic particle and a guidance molecule in a weight ratio of 1:0.0001-0.20 in water, organic or inorganic substance or the mixed solution thereof. The resultant targeted magnetic nanoparticle drug can realize targeted magnetic hyperthermia treatment and targeted magnetic thermoablation treatment and prevention on the tumors, and effectively kill the cancer cells, and cure the malignant tumors.
Owner:ZHU HONG

Generic Approach for Synthesizing Asymmetric Nanoparticles and Nanoassemblies

A generic route for synthesis of asymmetric nanostructures. This approach utilizes submicron magnetic particles (Fe3O4—SiO2) as recyclable solid substrates for the assembly of asymmetric nanostructures and purification of the final product. Importantly, an additional SiO2 layer is employed as a mediation layer to allow for selective modification of target nanoparticles. The partially patched nanoparticles are used as building blocks for different kinds of complex asymmetric nanostructures that cannot be fabricated by conventional approaches. The potential applications such as ultra-sensitive substrates for surface enhanced Raman scattering (SERS) have been included.
Owner:UCHICAGO ARGONNE LLC

Skeletally targeted nanoparticles

The invention provides methods and compositions for the delivery of bioactive factors to the systemic skeleton. The methods of the invention allow targeted delivery of bioactive factors to bone using nanocapsules comprised of amphipathic materials. Timed release of bioactive factors may also be used to increase the efficacy of treatment. The methods of the invention have wide applicability for the treatment or prevention of bone-associated maladies.
Owner:SOUTHWEST RES INST

Galactosamine and polydopamine modified liver cancer targeting nanoparticles as well as preparation method and application thereof

The invention discloses galactosamine and polydopamine modified liver cancer targeting nanoparticles as well as a preparation method and application thereof. The preparation method of the galactosamine and polydopamine modified liver cancer targeting nanoparticles comprises the following steps: taking polymer and a hydrophobic medicine, dissolving the polymer and the hydrophobic medicine into an organic solvent, stirring, dropwise adding the obtained solution into TPGS aqueous solution, stirring, carrying out reduced pressure volatilization, centrifuging, and abandoning supernate, so that polymer initial nanoparticles carrying the hydrophobic medicine are obtained; resuspending the initial nanoparticles in Tris buffer solution, adding dopamine hydrochloride for reacting, and centrifuging, so that hydrophobic-medicine-carrying nanoparticles wrapped by polydopamine are obtained; dispersing the hydrophobic-medicine-carrying nanoparticles wrapped by polydopamine into weakly alkaline aqueous solution, adding a liver cancer targeting ligand galactosamine, reacting, centrifuging, and carrying out freeze drying, so that the galactosamine and polydopamine modified liver cancer targeting nanoparticles are obtained. The preparation method of the galactosamine and polydopamine modified liver cancer targeting nanoparticles is simple and pollution-free; and the galactosamine and polydopamine modified liver cancer targeting nanoparticles have good liver targeting property, biological compatibility and biological degradability, can be used for targeting liver cancer and has treatment effect.
Owner:SHENZHEN BAINUO KANTAI BIOTECH CO LTD

Nuclear magnetic resonance sensor for detecting melamine based on magnetic nanoparticles, and preparation method and application thereof

The invention discloses a nuclear magnetic resonance sensor for detecting melamine based on magnetic nanoparticles. The nuclear magnetic resonance sensor is a Fe / Fe3O4 magnetic nanoparticle containing an acceptor unit which is capable of specific recognition of melamine and having water-solubility, superparamagnetism, uniform particle size distribution and a particle size of about 10 to 20 nm. A preparation method for the sensor comprises the following steps: preparation of a Fe / Fe3O4 magnetic nanoparticle through high temperature pyrolysis; preparation of Dopa-PEG and Dopa-acceptor unit by using N-hydroxy succinimide and 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride; and preparation of a target nanoparticle for preparation of the nuclear magnetic resonance sensor used for detecting melamine in virtue of coordination of oxygen and connection of the nanoparticle. The preparation method provided by the invention has the advantages of easiness, safety, economy and easy availability of raw materials and good process controllability. According to the invention, a novel prospect--a nanometer magnetic resonance sensor is provided for application of a nanometer magnetic resonance contrast agent material, and the research area of nano-materials is broadened.
Owner:SHANGHAI NORMAL UNIVERSITY

Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle

Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence
Owner:CEDARS SINAI MEDICAL CENT

Herceptin modified paclitaxel-carried targeting nanoparticle transfer system

The invention discloses a herceptin modified paclitaxel-carried targeting nanoparticle transfer system and a preparation method thereof. Nanoparticles (PLNs) with PLGA / Lipid core-shell structures are prepared by an improved classical emulsion solvent evaporation method, paclitaxel-carried polymer lipid nanoparticles are prepared by a binary organic solvent method, and herceptin modified paclitaxel-carried targeting nanoparticles (T=PCNs) are built by a chemical modification method. The prepared T=PCNs release drugs in vitro, sudden release rate within 24h is 41.2%, cumulative release rate within 120h is 73.4%, and cancer therapy is facilitated by drug release level. Cell experiment results indicate that the T=PCNs are fine in targeting property for highly expressed HER2 cancer cells and have an obvious killing function for the cancer cells. Safety and the targeting property of paclitaxel are greatly improved.
Owner:JILIN UNIV

Photothermal conversion nanoparticles for targeted thermal elimination of Tregs (regulatory T cells), preparation and application

The invention discloses photothermal conversion nanoparticles for targeted thermal elimination of Tregs. Hydrophilic functional groups grafted with long cycles and functional groups of targeted Tregs are arranged on the surfaces of the nanoparticles, and the particle sizes of the nanoparticles are within 2 to 100 nanometers; the nanoparticles comprise tungsten oxide nanoparticles or gold nanoparticles in a non-stoichiometric ratio, wherein the molecular formulae of the tungsten oxide nanoparticles in the non-stoichiometric ratio are WOx; the particle sizes of the tungsten oxide nanoparticles are within 2 to 100 nanometers; when the targeted nanoparticles are the gold nanoparticles, the particle sizes of the targeted nanoparticles are within 1 to 200 nanometers, and the shapes of the targeted nanoparticles are one or more of spheres, triangles or rod-like structures; according to the invention, the Tregs are removed from tumor tissues, so that the inhibition of the Tregs for the activity of cytotoxic T cells can be blocked, furthermore, heat produced by a photothermal therapy stimulates the activation of the cytotoxic T cells in peripheral blood to weaken the immune tolerance of tumors and further stimulate the anti-tumor immune response, thereby achieving a specific killing effect on tumor cells.
Owner:NANJING UNIVERSTIY SUZHOU HIGH TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products